AtriCure, Inc.

Equities

ATRC

US04963C2098

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2024-05-17 EDT			5-day change	1st Jan Change
23.14 ^USD	+2.25%		+3.77%	-35.16%

05-14	Transcript : AtriCure, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:15 AM
05-02	Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	MT

AtriCure, Inc. Provides Earnings Guidance for the Year 2024

May 01, 2024 at 04:01 pm

AtriCure, Inc. provided earnings guidance for the year 2024. Full year 2024 revenue is projected to be approximately $459 million to $466 million, reflecting growth of approximately 15% to 17% over full year 2023.

Latest news about AtriCure, Inc.

Transcript : AtriCure, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 10:15 AM	05-14
Needham Lowers AtriCure's PT to $40 From $46 Due to Peer Multiple Contraction, Keeps Buy Rating	05-02	MT
Earnings Flash (ATRC) ATRICURE Reports Q1 Revenue $108.9M, vs. Street Est of $106.9M	05-01	MT
Transcript : AtriCure, Inc., Q1 2024 Earnings Call, May 01, 2024	05-01
AtriCure, Inc. Provides Earnings Guidance for the Year 2024	05-01	CI
AtriCure, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-01	CI
Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	04-23	MT
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	04-18	CI
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	03-07	MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	02-27	CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	02-16	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	02-16	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	02-16	MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	02-15	MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024	02-15
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	02-15	MT
Atricure, Inc. Provides Earnings Guidance for 2024	02-15	CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	02-15	CI
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	01-22	MT
Transcript : AtriCure, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 07:30 AM	01-10
AtriCure Reports Higher Preliminary Q4, 2023 Revenue; Issues 2024 Revenue Guidance; Shares Rise	01-08	MT
AtriCure, Inc. and Its Wholly Owned Subsidiary, Atricure, LLC Enters into an Asset-Based Credit Agreement	01-08	CI
Atricure, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2023 and Provides Financial Guidance for the Year 2024	01-08	CI
AtriCure, Inc. Appoints Shlomi Nachman to its Board of Directors	01-04	CI
AtriCure's Q3 Adjusted Loss Narrows, Revenue Rises; Full-Year Guidance Adjusted	11-01	MT

Chart AtriCure, Inc.

Duration

Period

More charts

Company Profile

AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-29 - Leerink Partners Healthcare Crossroads Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for AtriCure, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

23.14 USD

Average target price

47.33 USD

Spread / Average Target

+104.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
ATRICURE, INC.	-35.16%	1.09B
ABBOTT LABORATORIES	-5.43%	182B
MEDTRONIC PLC	+4.30%	114B
BECTON, DICKINSON AND COMPANY	-3.09%	68.38B
DEXCOM, INC.	+5.86%	52.46B
CENCORA, INC.	+8.15%	44.25B
HOYA CORPORATION	+7.52%	43.55B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.69B
TERUMO CORPORATION	+17.85%	26.73B
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.79B

Other Medical Equipment, Supplies & Distribution